| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96ec3985e3ce9b24614fb87bf51a4f12 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-003 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 |
| filingDate |
2012-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf703e2d8278164ae40fd132db3aafdb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_112e68de65247d81a9b1605ae7787371 |
| publicationDate |
2012-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201249818-A |
| titleOfInvention |
Preparation of high-purity gadobutrol |
| abstract |
What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist ® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist ® . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I765913-B |
| priorityDate |
2011-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |